Protagen Hopes to Have Diagnostics Deal Inked by End of 2010, Says CEO

CEO Stefan Muellner told BioArray News last week that Protagen has shifted its business strategy from developing tests on its UniArray protein chip platform to discovering panels of biomarkers that can later be brought to market by bigger firms.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.